

Aminonaphthalene 2-Cyanoacrylate (ANCA) Probes Fluorescently Discriminate between Amyloid- β and Prion Plaques in Brain

Kevin Cao,[†] Mona Farahi,[‡] Marianna Dakanali,[†] Willy M. Chang,[†] Christina J. Sigurdson,[‡] Emmanuel A. Theodorakis,^{*,†} and Jerry Yang^{*,†}

[†]Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0358, United States

[‡]Department of Pathology, University of California, San Diego, La Jolla, California 92093-0612, United States

Supporting Information

ABSTRACT: A major challenge for diagnosing and monitoring the progression of amyloid-based diseases is the capability to distinguish between amyloid deposits that are associated with related, but distinctly different, diseases. Here, we demonstrate that aminonaphthalenyl 2-cyanoacrylate-based probes can fluorescently discriminate between different types of amyloid deposits in brain. The discriminating capability of these molecular rotors is due to the stabilization of the ground versus excited states of these probes as a function of the polarity of their microenvironment (i.e., within the binding pocket on the amyloid). This property makes it possible, for the first time, to estimate the inherent static relative permittivity (ϵ_0) of the binding pocket of each amyloid within tissue. The capability to selectively follow the deposition of specific amyloids in tissue may provide important information for therapeutic development that is not readily accessible from currently available technology.

Amyloid plaque accumulation in the brain is the hallmark of many neurodegenerative disorders, including Alzheimer's disease (AD) and Creutzfeldt–Jakob disease (CJD).^{1,2} Approaches to clinically diagnose and monitor the progression of these diseases include targeting of amyloid deposits with small-molecule imaging agents.^{3–5} Along these lines, an amyloid-labeling probe for use in positron emission tomography (PET) has recently been shown to be a clinically useful diagnostic agent for AD.^{6,7} While PET imaging represents a great first step toward the diagnosis of neurodegenerative diseases, this technique is limited by the binary nature of the radioactive signal that does not allow for discrimination between amyloids associated with different, but closely related, diseases. Alternative techniques that can discern between different types of amyloids may offer important information necessary to develop effective treatment strategies that are tailored to specific diseases.

Fluorescence-based imaging of amyloids has emerged as a potentially lower cost, more accessible, and non-radioactive alternative to PET.^{8–16} In principle, fluorescence-based probes offer an advantage over their radioactive counterparts since their fluorescence profile could be used to distinguish different amyloids in tissue. Here, we report the ability of aminonaphthalenyl 2-cyanoacrylate (ANCA)-based probes (for a generic structure see Table 1) to fluorescently discriminate




Figure 1. True color imaging of amyloid deposits in tissue stained with ANCA probe 1. (A) A β deposits in the hippocampus of an AD mouse model. (B) PrP^{Sc} deposits in the corpus callosum of a prion-infected mouse. (C) *Ex vivo* fluorescence spectra of stained deposits showing distinct emission maxima for A β and PrP^{Sc}. Scale bar = 100 μ m. NFI = normalized fluorescence intensity.

Table 1. Structure, Binding, and Emission Properties for ANCA Probes 1–3 Bound to Amyloid Proteins^a

Generic structure of ANCA probes		Em _{max} of plaques stained in tissue		
Cmpd	X	K _d for binding to A β fibrils (μ M)	A β (nm)	PrP ^{Sc} (nm)
1		1.4 $\pm$ 0.2	535 $\pm$ 3	554 $\pm$ 2
2		13.8 $\pm$ 3.1	525 $\pm$ 4	541 $\pm$ 4
3		4.6 $\pm$ 1.3	515 $\pm$ 4	538 $\pm$ 3

^aSee Figures S2 and S3 for additional details.

between deposits in brain sections derived from amyloid- β (A β) peptides associated with AD or from prion (PrP^{Sc}) proteins associated with prion disease (Figure 1).

We previously reported that ANCA probes 1–3 (Table 1) could label A β plaques in human brain sections from AD

patients.¹⁵ Brain sections stained with these probes showed good overlap of fluorescence with a mouse monoclonal antihuman A β IgG, demonstrating that these probes could mark the location of A β deposits with good specificity compared to surrounding background tissue. The ANCA probes are members of the molecular rotors family of fluorophores and fluoresce by a photon-induced dipole mechanism,^{14,17} where the electron-rich amine functionality, attached to the naphthalene moiety, can donate electron density to the electron-deficient cyano ester through the π -system of the ANCA scaffold (Table 1).^{15,18} The emission of these compounds is enhanced upon restriction of the rotation around the single bonds between the donor (amine) and acceptor (cyano ester) groups. The ANCA probes, therefore, exhibit a large enhancement in fluorescence properties upon binding to amyloid substrates compared to the weaker fluorescence of the free compounds when in solution (see Supporting Information, Figure S1).

To explore the capability of the ANCA probes to fluorescently label amyloid deposits from proteins other than A β in tissue, we compared fluorescence micrograph images of plaques derived from A β (Figure 1A) and PrP^{Sc} (Figure 1B) stained with **1** in frozen brain sections (i.e., unfixed) from mouse models for AD and prion disease.^{19–21} Importantly, **1** exhibited excellent capability to label amyloid plaques in both tissues and displayed a visually observable difference in the color emitted upon staining of the plaques. Probes **2** and **3** exhibit similar properties (see Figure S3).

Table 1 displays that the ANCA probes bound to amyloid deposits exhibit a difference in maximal emission wavelength (λ_{max}) of ~ 20 nm, depending on the type of amyloid protein present in the plaque. Remarkably, the variability in the observed λ_{max} between plaques was quite narrow (± 2 – 3 nm from inspection of ≥ 25 plaques in each sample). Moreover, A β plaques stained with **1** from different parts of the brain (e.g., hippocampus, hypothalamus, cortex) from the same mouse all exhibited essentially the same emission λ_{max} (± 3 nm). Additionally, prion plaques stained with **1** from the corpus callosum of different mice also exhibited essentially the same emission λ_{max} (± 2 nm). In contrast, we did not observe such fluorescence discrimination upon staining of the plaques with Congo red (a common histological staining agent for amyloid deposits, see Figure S4). These surprising results prompted us to investigate the origin of fluorescence discrimination by **1**–**3**.

Previous studies in solution have shown that the small differences in the environment of proteins^{22–26} and lipids²⁷ can affect the Stokes shift of bound fluorophores.²⁸ If the time dependence of fluorescence polarization of probes **1**–**3** can be neglected—that is, if we assume that any reorientation of molecules within the binding pocket of the amyloid proteins is fast compared to the lifetime of the excited state of the probes—the dependence of the polar environment on the frequency of the absorbance and fluorescence emission spectra of **1**–**3** can be approximated by the Ooshika–Lippert–Mataga (OLM) equation:^{27,29,30}

$$\Delta\nu = \frac{2(\mu_e - \mu_g)^2}{ha^3} \left(\frac{\epsilon_0 - 1}{2\epsilon_0 + 1} - \frac{n^2 - 1}{2n^2 + 1} \right) \quad (1)$$

where $\Delta\nu$ is the average frequency of the Stokes shift,³¹ μ_e and μ_g are the dipole moments of the molecules in the excited state and ground state, respectively, h is Planck's constant, a is the approximate radius of the molecules assuming a spherical cavity

with a rigid dipole at the center, ϵ_0 is the static relative permittivity (i.e., dielectric constant) of the dielectric continuum surrounding the molecules, and n is the refractive index of the medium.

Since the frequency of absorption for molecules **1**–**3** remains relatively constant when measured in different solvents of various polarities, we found an approximately linear relationship between the Stokes shifts of **1**–**3** and their observed λ_{max} for fluorescence emission (see Figure S5). This linear correlation allows us to use only the λ_{max} of emission to analyze the effect of the polar environment within the binding pockets of the amyloids on the fluorescence properties of **1**–**3**.³² Equation 1 could, therefore, be simplified to²⁷

$$\frac{1}{\lambda_{\text{max}}(\text{Em})} = C_1 \left(\frac{\epsilon_0 - 1}{2\epsilon_0 + 1} - \frac{n^2 - 1}{2n^2 + 1} \right) + C_2 \quad (2)$$

where C_1 and C_2 are constants that reflect several inherent properties of the ANCA probes.

Figure 2A–C (open circles) plots the dependence of $1/\lambda_{\text{max}}$ for fluorescence emission of **1**–**3** in solvents of various




Figure 2. Dependence of fluorescence emission of probes **1**–**3** on the polarity of different organic solvents. (A–C) Graphs of the relationship between $1/\lambda_{\text{max}}$ for emission of **1**–**3** as functions of solvent static relative permittivity (ϵ_0), with ($\square$) or without ($\circ$) the contribution of refractive index (n). For each graph, the linear fits of the data according to eq 2 are shown in red, excluding the contribution from n . (D) Estimated ϵ_0 for the binding pockets of A β and PrP^{Sc} deposits extrapolated from the observed λ_{max} for emission of **1**–**3** in tissue samples.

polarities (see Figure S6) as a function of the static relative permittivity (ϵ_0) and refractive index (n) of each solvent according to eq 2. The observed linear correlation shown in Figure 2A–C suggests that the OLM equation (eq 1) describes fairly well the dependence of the observed fluorescence of compounds **1**–**3** on the polarity of their surrounding environment. These results suggest that the origin of the observed fluorescence discrimination between the two different types of amyloid deposits using probes **1**–**3** could indeed be simply explained by small differences in the polar environment within the binding pockets of the amyloid proteins.

In order to gain some additional insight into the nature of the polar environment within the binding pockets of the amyloid

tissues, we re-plotted the dependence of $1/\lambda_{\max}$ for fluorescence emission of 1–3 in different solvents as a function of ϵ_0 only, while ignoring the refractive index of the solvent (Figure 2A–C, open circles).²⁷ We found that the linear fit of $1/\lambda_{\max}$ versus $(\epsilon_0 - 1)/(2\epsilon_0 + 1)$ was consistently better compared to the results when the refractive index was included, as in eq 2 (see Figure S7). This suggests that the static relative permittivity (ϵ_0) dominated the dependence of the polar environment on the $\lambda_{\max}$ for fluorescence emission of 1–3.³³ This simple relationship between $\lambda_{\max}$ and ϵ_0 , hence, made it possible to estimate the static relative permittivity of the binding pockets of the two different amyloids in tissue by the observed emission maxima of plaques stained with 1–3 (Figure 2D). Satisfyingly, the estimated ϵ_0 values for the two amyloids were in fairly good agreement (given the assumptions and approximations made in eqs 1 and 2), regardless of which ANCA probe was used for measurement. The data reveal that both amyloid binding pockets are relatively hydrophobic as expected, but that the permittivity within the binding pocket of prion plaques is roughly 2-fold greater than the permittivity within the binding pocket of $A\beta$ plaques. To provide a reference point for calibration, we estimate the dielectric constants of the binding pocket of $A\beta$ and prion plaques to be roughly similar to those of diethyl ether ($\epsilon_0 = 4.27$) and tetrahydrofuran ($\epsilon_0 = 7.52$), respectively.³⁴

Although small differences in the polar environment within the binding pockets of the amyloids can reasonably account for the observed fluorescence discrimination of the amyloids with probes 1–3, we tested another plausible explanation for this observation. We considered that acid–base interactions between the amyloid and the probes could affect the electron donor capability of the amine group of these probes, thus affecting their observed emission profiles. To investigate this possibility, we examined the excitation and emission profiles of 1–3 as a function of pH in free aqueous solution (Figure 3).

Figure 3A,C shows that probes 1 and 2 exhibit a sharp 100–125 nm change in excitation maxima at a pH of ~ 4.2 and ~ 1.7 , respectively. These changes presumably reflect the protonation of the nitrogen donor of the piperidine in 1 or morpholine in 2, and provide an estimate of the pK_a 's of the protonated forms of these groups. A much smaller change in excitation $\lambda_{\max}$ (~ 10 nm) was observed for 3 at a pH of ~ 6.9 , which presumably reflects the pK_a of the protonated *N*-methyl tertiary amine. More importantly, the emission profiles of 1–3 (Figure 3B,D,F) in acidic (pH 3.8) versus neutral (pH 7.8) solutions indicate that only probe 1 should exhibit a strong (~ 125 nm) difference in emission $\lambda_{\max}$ when bound to amyloid plaques, if the origin of fluorescence discrimination was due to an acid–base interaction.³⁵ Since we observe a difference (~ 20 nm) in emission $\lambda_{\max}$ between $A\beta$ versus prion plaques upon staining with all three probes 1–3, it is unlikely that the origin of fluorescence discrimination is due to acid–base interactions between the probes and the proteins within the binding pocket of the amyloid deposits.

In conclusion, we present a set of fluorescent amyloid-binding probes that can report a different color of fluorescence emission when bound to different types of amyloid deposits in tissue samples. The origin of this fluorescence discrimination most likely arises from the sensitivity of these probes to the polar environment within the binding pocket of an amyloid plaque. Subtle changes to the structure (i.e., electron donor moiety) in these ANCA probes make it possible to tune the spectral window of fluorescence discrimination. The strong




Figure 3. Plots of absorption (A,C,E) and emission (B,D,F) $\lambda_{\max}$ versus pH of probes 1–3. For fluorescence emission spectra, we chose an excitation $\lambda_{\max}$ that was maximized at pH 3.8 and 7.8.

correlation between fluorescence emission of the probes and polarity of the environment afforded estimates of the static relative permittivity of the binding pocket in the amyloid plaques. Analysis of amyloid deposits in tissue revealed that the prion deposits exposed a significantly more polar environment to the probes than the $A\beta$ deposits. This previously unreported, fundamental difference between these two types of amyloids makes it possible to distinguish them in tissue by simple inspection of the fluorescence emission of molecules that target them. Given the recent findings that amyloid deposition in the brain of AD patients may be paralleled by deposition of amyloids in the retinal tissue^{36–41} or lens^{42,43} of the eye, optical inspection of amyloid deposits in the eye may represent an exciting opportunity for diagnosing and monitoring the progression of amyloid-associated diseases. Fluorescent amyloid imaging agents such as the ANCA compounds may, therefore, have practical ophthalmic applications in living patients to help distinguish between closely related diseases where the symptoms and pathological characteristics show many similarities.^{44,45} Efforts to examine the scope of these probes for discriminating amyloid deposits associated with diseases other than Alzheimer's and prion diseases are currently underway.

■ ASSOCIATED CONTENT

● Supporting Information

Syntheses of 1–3, protocols for staining of plaques in neuronal tissue, and details of binding and fluorescence studies. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

jerryyang@ucsd.edu; etheodor@ucsd.edu

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support from the NIH [CA 133002 (E.A.T.) and R01NS069566 (C.S.)] is gratefully acknowledged. We also thank the NSF for financial support [CHE-9709183, CHE-0741968, and CHE-0847530 (J.Y.)]. We thank Dr. Christina C. Capule for help with the binding studies. We also thank Dr. Edward Koo for the brain samples from AD transgenic mice.

■ REFERENCES

- (1) Ross, C. A.; Poirier, M. A. *Nature Med.* **2004**, S10–S17.
- (2) Irvine, G. B.; El-Agnaf, O. M.; Shankar, G. M.; Walsh, D. M. *Mol. Med.* **2008**, *14*, 451–464.
- (3) Nordberg, A. *Curr. Opin. Neurol.* **2007**, *20*, 398–402.
- (4) Ono, M.; Saji, H. *Int. J. Mol. Imag.* **2011**, 543267.
- (5) Xiong, K.-L.; Yang, Q.-W.; Gong, S.-G.; Zhang, W.-G. *Nucl. Med. Commun.* **2010**, *31*, 4–11.
- (6) Clark, C. M.; Schneider, J. A.; Bedell, B. J.; Beach, T. G.; Bilker, W. B.; Mintun, M. A.; Pontecorvo, M. J.; Hefti, F.; Carpenter, A. P.; Flitter, M. L.; Krautkramer, M. J.; Kung, H. F.; Coleman, R. E.; Doraiswamy, P. M.; Fleisher, A. S.; Sabbagh, M. N.; Sadowsky, C. H.; Reiman, E. P.; Zehntner, S. P.; Skovronsky, D. M. *J. Am. Med. Assoc.* **2011**, *305*, 275–283.
- (7) Camus, V.; Payoux, P.; Barre, L.; Desgranges, B.; Voisin, T.; Tauber, C.; Joie, R.; Tafani, M.; Hommet, C.; Chetelat, G.; Mondon, K.; Sayette, V.; Cottier, J. P.; Beaufils, E.; Ribeiro, M. J.; Gissot, V.; Vierron, E.; Vercouillie, J.; Vellas, B.; Eustache, F.; Guilloteau, D. *Eur. J. Nucl. Med. Mol. Imaging* **2012**, *39*, 621–631.
- (8) Hintersteiner, M.; Enz, A.; Frey, P.; Jaton, A.-L.; Kinzy, W.; Kneuer, R.; Neumann, U.; Rudin, M.; Staufenbiel, M.; Stoekli, M.; Wiederhold, K.-H.; Gremlich, H.-U. *Nat. Biotechnol.* **2005**, *23*, 577–583.
- (9) Nesterov, E. E.; Skoch, J.; Hyman, B. T.; Klunk, W. E.; Bacskai, B. J.; Swager, T. M. *Angew. Chem., Int. Ed.* **2005**, *44*, 5452–5456.
- (10) Raymond, S. B.; Skoch, J.; Hills, I. D.; Nesterov, E. E.; Swager, T. M.; Bacskai, B. J. *Eur. J. Nucl. Med. Mol. Imaging* **2008**, *35*, S93–S98.
- (11) Li, Q.; Lee, J. S.; Ha, C.; Chan, B. P.; Yang, G.; Wen, B. G.; Chang, Y. T. *Angew. Chem., Int. Ed.* **2004**, *43*, 6331–6335.
- (12) Ran, C.; Xu, X.; Raymond, S. B.; Ferrara, B. J.; Neal, K.; Bacskai, B. J.; Medarova, Z.; Moore, A. J. *Am. Chem. Soc.* **2009**, *131*, 15257–15261.
- (13) Ono, M.; Ishikawa, M.; Kimura, H.; Hayashi, S.; Matsumura, K.; Watanabe, H.; Shimizu, Y.; Cheng, Y.; Cui, M.; Kawashima, H.; Saji, H. *Bioorg. Med. Chem.* **2010**, *20*, 3885–3888.
- (14) Sutharsan, J.; Lichlyter, D.; Wright, N. E.; Dakanali, M.; Haidekker, M. A.; Theodorakis, E. A. *Tetrahedron* **2010**, *66*, 2582–2588.
- (15) Chang, W. M.; Dakanali, M.; Capule, C. C.; Sigurdson, C. J.; Yang, J.; Theodorakis, E. A. *ACS Chem. Neurosci.* **2011**, *2*, 249–255.
- (16) Aslund, A.; Sigurdson, C. J.; Klingstedt, T.; Grathwohl, S.; Bolmont, T.; Dickstein, D. L.; Glimsdal, E.; Prokop, S.; Lindgren, M.; Konradsson, P.; Holtzman, D. M.; Hof, P. R.; Heppner, F. L.; Gandy, S.; Jucker, M.; Aguzzi, A.; Hammarstrom, P.; Nilsson, K. P. R. *ACS Chem. Biol.* **2009**, *4*, 673–684.
- (17) Haidekker, M. A.; Theodorakis, E. A. *Org. Biomol. Chem.* **2007**, *5*, 1669–1678.
- (18) Sutharsan, J.; Dakanali, M.; Capule, C. C.; Haidekker, M. A.; Yang, J.; Theodorakis, E. A. *ChemMedChem* **2010**, *5*, 56–60.
- (19) Sigurdson, C. J.; Aguzzi, A. *Biochim. Biophys. Acta* **2007**, *1772*, 610–618.
- (20) Williams, E. S. *Vet. Pathol.* **2005**, *42*, 530–549.
- (21) Here, we used tissues derived from mice since human tissues containing prion deposits pose significant safety concerns and are not readily available. In the case of A β deposits, we chose to use brain sections from mice in order to maintain the same organism for comparison with brain sections containing prion deposits.
- (22) Mishra, R.; Sjölander, D.; Hammarström, P. *Mol. Biosyst.* **2011**, *7*, 1232–1240.
- (23) Brandenburg, E.; Berlepsch, H.; Koks, B. *Mol. Biosyst.* **2012**, *8*, 557–564.
- (24) Benzeid, H.; Mothes, E.; Essassi, E. M.; Faller, P.; Prati, G. *C.R. Chimie* **2012**, *15*, 79–85.
- (25) Nilsson, K. P. R. *FEBS Lett.* **2009**, *583*, 2593–2599.
- (26) Nilsson, K. P. R.; Hammarstrom, P.; Ahlgren, F.; Herland, A.; Schnell, E. A.; Lindgren, M.; Westermark, G. T.; Inganas, O. *ChemBioChem* **2006**, *7*, 1096–1104.
- (27) Kimura, Y.; Ikegami, A. *J. Membr. Biol.* **1985**, *85*, 225–231.
- (28) Nile red has previously been reported to emit fluorescence at different wavelengths upon binding to a few different amyloid fibrils in solution. Nile red was not, however, capable of discriminating A β versus prion fibrils. Additionally, Nile red is not suitable for histological studies due to its poor selectivity for binding to amyloid plaques compared to other biologics present in tissue. See ref 22.
- (29) Mataga, N.; Kaifu, Y.; Koizumi, M. *Bull. Chem. Soc. Jpn.* **1955**, *28*, 690–691.
- (30) Bagchi, B.; Oxtoby, D. W.; Fleming, G. R. *Chem. Phys.* **1984**, *86*, 257–267.
- (31) Lakowicz, J. R. *Principles of fluorescence spectroscopy*; Kluwer Academic/Plenum: New York, 1999.
- (32) The linear relationship between Stokes shifts of 1–3 and their observed λ_{max} for fluorescence emission was essential to estimate ϵ_0 for the binding pocket of the amyloids since the background absorption of tissue and limitations in the laser source for excitation of fluorophores in the confocal microscope would not allow for measurement of the Stokes shift of 1–3 in the tissue samples.
- (33) This property is relatively common for many fluorophores. See ref 31.
- (34) Permittivity (Dielectric Constants) of Liquids. In *CRC Handbook of Chemistry and Physics*, 92nd ed.; Haynes, W. M., Ed.; CRC Press/Taylor and Francis: Boca Raton, FL, 2012.
- (35) Here, we assume that extremely acidic environments of pH < 1.7 within the binding pocket of amyloid deposits is unlikely.
- (36) Cordeiro, M. F.; Guo, L.; Coxon, K. M.; Duggan, J.; Nizari, S.; Normando, E. M.; Sensi, S. L.; Sillito, A. M.; Fitzke, F. W.; Salt, T. E.; Moss, S. E. *Cell Death Dis.* **2010**, *1*, e3.
- (37) Koronyo-Hamaoui, M.; Koronyo, Y.; Ljubimov, A. V.; Miller, C. A.; Ko, M. K.; Black, K. L.; Schwartz, M.; Farkas, D. L. *Neuroimage* **2011**, *54*, S204–S217.
- (38) Ning, A.; Cui, J. Z.; To, E.; Hsiao Ashe, K.; Matsubara, J. A. *Invest. Ophthalmol. Vis. Sci.* **2008**, *49*, 5136–5143.
- (39) Shimazawa, M.; Inokuchi, Y.; Okuno, T.; Nakajima, Y.; Sakaguchi, G.; Kato, A.; Oku, H.; Sugiyama, T.; Kudo, T.; Ikeda, T.; Takeda, M.; Hara, H. *J. Neurochem.* **2008**, *107*, 279–290.
- (40) Guo, L.; Duggan, J.; Cordeiro, M. F. *Curr. Alzheimer Res.* **2010**, *7*, 3–14.
- (41) Guo, L.; Salt, T. E.; Luong, V.; Wood, N.; Cheung, W.; Maass, A.; Ferrari, G.; Russo-Marie, F.; Sillito, A. M.; Cheetham, M. E.; Moss, S. E.; Fitzke, F. W.; Cordeiro, M. F. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 13444–13449.
- (42) Goldstein, L. E.; Muffat, J. A.; Cherny, R. A.; Moir, R. D.; Ericsson, M. H.; Huang, X.; Mavros, C.; Coccia, J. A.; Faget, K. Y.; Fitch, K. A.; Masters, C. L.; Tanzi, R. E.; Chylack, L. T.; Bush, A. I. *Lancet* **2003**, *361*, 1258–1265.
- (43) Moncaster, J. A.; Pineda, R.; Moir, R. D.; Lu, S.; Burton, M. A.; Ghosh, J. G.; Ericsson, M.; Soscia, S. J.; Mocofanescu, A.; Folkert, R. D.; Robb, R. M.; Kuszak, J. R.; Clark, J. I.; Tanzi, R. E.; Hunter, D. G.; Goldstein, L. E. *PLoS One* **2010**, *5*, e10659.
- (44) Feany, M. B.; Dickson, D. W. *Ann. Neurol.* **1996**, *40*, 139–148.
- (45) Skovronsky, D. M.; Lee, V. M.-Y.; Trojanowski, J. Q. *Annu. Rev. Pathol. Mech. Dis.* **2006**, *1*, 151–170.

■ NOTE ADDED AFTER ASAP PUBLICATION

A typographical error in the title was corrected October 9, 2012.